Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
DATAMONITOR HEALTHCARE
Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Meet the team
Julie Guan (China)
Head of Strategic Accounts
Citeline
Youmin Zhu (China)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我們提供各產品的使用培訓支持，請點擊下列查閲相關培訓資源，若有特定培訓需求或安排則可聯絡：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登錄問題，請切換至Meet the Team版面並聯絡對接服務團隊，或可聯絡全球/亞太客服團隊：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作爲重點合作夥伴，貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復（工作日），并爲您提供信息收集或專業見解，最終助您做出更快、更明智的業務決策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持，您的個人資訊與提問内容均會被嚴格保密。
Latest Pharma Monthly Newsletter
Edition: August 2026
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Webinar: The China Advantage: Rewriting Clinical Development (SEP 24, 10am EST | Register)
- Webinar: Global Clinical Trial Disclosure: Are You Casting a Line or a Net? (SEP 29, 11am EST | Register)
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- M&A: Curium to Acquire Lantheus for up to $8B
- M&A: Integer Holdings to be Taken Private Through KKR Buy-Out for $5.7B
- M&A: Jazz to Acquire Actio Biosciences for up to $1.3B
- Licensing: Genentech Enters $2.3B Licensing Agreement with Hanmi for Obesity Candidate ($190M upfront)
- Licensing: Alphamab Oncology Licenses TROP2/HER3 Bispecific ADC to Pathos AI in Potential $2.2B Deal ($125M upfront)
- Licensing: SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim' from Biohaven totalling $795M ($400M upfront)
- Financing: Braveheart Bio Nets $409M in Nasdaq IPO; Overallotment Fully Exercised
- Financing: Vaderis Raises $152M in Series B Financing
- Financing: Expedition Therapeutics Raises $115M in Oversubscribed Series B Round
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Positive: Agenus | BOT+BAL Updated Phase 2 NEST publication demonstrates zero recurrences and deep pathologic responses in resectable colon cancer
- Positive: AstraZeneca | Tagrisso + Orpathys delivers dual PFS and OS win in MET-driven post-Tagrisso NSCLC
- Positive: Moderna | mRNA cancer therapy delivers first Phase III win, validating the intismeran platform and extending Merck's melanoma franchise
- Positive: Alumis | Alumis envudeucitinib's long-term data supports a credible third TYK2 alternative, but not as category leader
- Positive: Agenus | Off-the-Shelf iNKT Cell Therapy Shows Early Promise Where No Approved Treatment Exists
- Negative: Tenax | TNX-103 misses Phase III LEVEL primary endpoint in PH-HFpEF but efficacy and biomarker signals support development in enriched population
- Negative: Bausch + Lomb | Phase II miss at day 29 narrows lifitegrast + perfluorohexyloctane dual-action dry eye claim to speed of onset
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Report: The Use of AI in Pharmaceutical Commercialization: Insights from the Field (Link)
- Report: Radiopharmaceuticals Landscape Snapshot (Link)
- Report: Dealmaking Quarterly Statistics, Q2 2026
- Report: Financing Quarterly Statistics, Q2 2026
- Report: What Good LBE Forecasting Actually Looks Like
- Report: Epi & Market Forecast - Breast Cancer HER2+ | Depression | Systemic Lupus Erythematosus
- Report: KOL Interview - HER2-Positive Breast Cancer
Latest Editorial Podcasts
